Speaker Profile

Ph.D., Principal Scientist, Horizon, PerkinElmer

Emily has managed projects involving the development and application of gene engineering and gene modulation technologies including Dharmacon™ ON-TARGETplus™ siRNA and Accell™ siRNA, as well as the introduction of Dharmacon™ Edit-R™, the first rationally-designed, genomewide library of synthetic CRISPRs for gene disruption. She received a Ph.D. in Biochemistry from the University of Colorado at Boulder on the structure and function of protein:single-stranded DNA interactions at telomeres. She has worked extensively on the mechanism, function, specificity, and delivery of RNAi as well as its applications. She is an inventor on many issued patents and has authored peer-reviewed publications in the fields of both RNAi and CRISPR.

Pin-point™ – Modular Base Editing for Clinical Applications
Pin-point™ uses aptameric guide RNA for deaminase recruitment. We demonstrate in CAR-T cells multitargeting of several therapeutically relevant loci, retaining proliferative and cytotoxic ability, including advantages over Cas9. Aptameric recruitment enables simultaneous knock-in and knockout and allows targeting polygenic disorders.

 Session Abstract – PMWC 2022 Silicon Valley

Track Chair:
Vanessa Soros, Graphite Bio


  • Gene & Cell Therapies Overview
    - Janice Chen, Mammoth
  • Advances in Gene & Cell Therapies
    Session Chair: Vanessa Soros, Graphite Bio
    - Mark McKee, Intellia Tx
    - Amy Simon, Beam Therapeutics
    - Eric Ostertag, Poseida Therapuetics
  • Translating CGT to the Clinic (PANEL)
    Session Chair: Nicole K. Paulk, UCSF
    - Matthew Porteus, Stanford
    - Eric Crombez, Ultragenyx Gene Therapy
    - Peter Francis, 4D Molecular Therapeutics
    - Erandi De Silva, Forge Biologics
    - Patrice Hugo, Q2 Solutions
  • PMWC Showcase
    - Yuri Fesko, Labcorp
    - Yan Zhang, Mission Bio
    - Anil Narasimha, Mekonos Inc.
    - Emily Anderson, Horizon, a PerkinElmer Company
    - Peter Marinkovich, Stanford
    - Jesse Salk, Twinstrand
    - William Shrader, AcureX Therapeutics
  • Past, Present and Future of CRISPR Where will CRISPR Take Us and How is the Technology Evolving to Realize its Full Potential (PANEL)
    Session Chair: Janice Chen, Mammoth
    - Kiana Aran, Cardea Bio
    - Mark McKee, Intellia Tx
    - Josh Lehrer, Graphite Bio